

**Beneficiary Information**

1. Beneficiary Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Beneficiary ID #: \_\_\_\_\_ 4. Beneficiary Date of Birth: \_\_\_\_\_ 5. Beneficiary Gender: \_\_\_\_\_

**Prescriber Information**

6. Prescriber Name: \_\_\_\_\_ NPI #: \_\_\_\_\_  
Mailing address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_  
7. Requester Contact Information: \_\_\_\_\_  
Name: \_\_\_\_\_ Phone #: \_\_\_\_\_ Fax #: \_\_\_\_\_

**Drug Information**

8. Drug Name: \_\_\_\_\_ 9. Strength: \_\_\_\_\_ 10. Quantity per 30 days: \_\_\_\_\_  
11. Length of Therapy: \_\_\_up to 30 days \_\_\_60 days \_\_\_90 days \_\_\_120 days \_\_\_180 days \_\_\_Other: \_\_\_\_\_

**Clinical Information**

**Initial Request: Wegovy for Cardioprotection**

1. Are medical records attached ? Yes\_\_\_ No\_\_\_ **\*\*\*Medical records are required for Cardioprotection prior authorization review.\*\*\***
2. What is beneficiary's baseline weight and BMI? **Weight**\_\_\_\_\_ **Date**\_\_\_\_\_ **BMI**\_\_\_\_\_ **Date**\_\_\_\_\_
3. Is the beneficiary 45 years of age or older? Yes\_\_\_ No\_\_\_
4. Does the beneficiary have established cardiovascular disease (CVD) defined as having a history of myocardial infarction, stroke, or symptomatic peripheral arterial disease? Yes\_\_\_ No\_\_\_  
**List diagnosis:** \_\_\_\_\_
5. Does the beneficiary have a personal or family history of medullary thyroid carcinoma? Yes\_\_\_ No\_\_\_
6. Does the beneficiary have multiple endocrine neoplasia syndrome type 2? Yes\_\_\_ No\_\_\_
7. Does the beneficiary have at least 3 months of lifestyle modifications prior to starting Wegovy? Yes\_\_\_ No\_\_\_
8. Is the beneficiary using Wegovy in combo with a reduced calorie diet and increased physical activity unless physical activity is not clinically appropriate at the time GLP1 therapy commences? Yes\_\_\_ No\_\_\_

**Initial Request: Wegovy for NASH/MASH**

1. Are medical records attached ? Yes\_\_\_ No\_\_\_ **\*\*\*Medical records are required for NASH/MASH prior authorization review.\*\*\***
2. Does the beneficiary have a diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH), or metabolic dysfunction associated steatohepatitis (MASH)? Yes\_\_\_ No\_\_\_
3. Does the beneficiary have a FIB-4 score consistent with stage F1, F2, or F3 fibrosis adjusted for age? Yes\_\_\_ No\_\_\_
4. Has the beneficiary had one of the following tests? Select which:  
\_\_\_ A liver biopsy  
\_\_\_ Vibration-controlled transient elastography (VCTE)  
\_\_\_ Enhanced liver fibrosis (ELF) score  
\_\_\_ Magnetic resonance elastography (MRE)
5. Is the beneficiary 18 years of age or older? Yes\_\_\_ No\_\_\_
6. What is the beneficiary's baseline BMI prior to beginning therapy? **BMI**\_\_\_\_\_ **Date**\_\_\_\_\_
7. Is the beneficiary of South Asian, Southeast Asian, or East Asian descent? Yes\_\_\_ No\_\_\_
8. Is the beneficiary female with alcohol consumption less than 20 grams/day? Yes\_\_\_ No\_\_\_
9. Is the beneficiary male with alcohol consumption less than 30 grams/day? Yes\_\_\_ No\_\_\_
10. Is the beneficiary being monitored for development of and/or treated for any comorbid conditions (e.g., cardiovascular disease, diabetes, dyslipidemia, hypertension)? Yes\_\_\_ No\_\_\_
11. Does the beneficiary have decompensated cirrhosis? Yes\_\_\_ No\_\_\_
12. Does the beneficiary have moderate to severe hepatic impairment (Child-Pugh Class B or C)? Yes\_\_\_ No\_\_\_
13. Does the beneficiary have any other liver disease? Yes\_\_\_ No\_\_\_ **List:** \_\_\_\_\_
14. Is Wegovy being prescribed by or in consultation with a specialist in the beneficiary's diagnosis (e.g., hepatologist, gastroenterologist)?  
Yes\_\_\_ No\_\_\_

**Continuation Request: Wegovy for Cardioprotection and NASH/MASH**

1. Are medical records attached? Yes\_\_\_ No\_\_\_ **\*\*\*Medical records are required for prior authorization review.\*\*\***
2. Has the beneficiary been previously approved for the requested agent through Medicaid's Prior Authorization process for the covered indications that went into effect 10/01/2025 [Note: beneficiaries not previously approved for the requested agent will require initial evaluation review]? Yes\_\_\_ No\_\_\_
3. Has medical documentation that beneficiary has improved while on the medication been included with this request? Yes\_\_\_ No\_\_\_
4. Are individual clinical goals set by the provider being met? Yes\_\_\_ No\_\_\_
5. Is the beneficiary continuing to make adequate progress towards treatment goals? Yes\_\_\_ No\_\_\_
6. Is the product prescribed FDA approved for the indication, age, weight (if applicable) and not exceeding dosing limits per the prescribing information per the clinical conditions for use? Yes\_\_\_ No\_\_\_
7. Is the beneficiary currently on and will continue lifestyle modification including structured nutrition and physical activity unless physical activity is not clinically appropriate? Yes\_\_\_ No\_\_\_
8. Will the beneficiary be using the requested agent with another GLP-1? Yes\_\_\_ No\_\_\_
9. Does the beneficiary have any FDA-labeled contraindications to the requested agent? Yes\_\_\_ No\_\_\_
10. Has the provider performed a review of the beneficiary's medication list for possible dose reductions or discontinuation of medications for comorbid conditions, which are no longer needed or able to be reduced due to clinical effects of receiving the medication? Yes\_\_\_ No\_\_\_

Signature of Prescriber: \_\_\_\_\_

Date: \_\_\_\_\_

**\*Prescriber signature mandatory**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.